Published in Diabetes Res Clin Pract on October 14, 2011
Studies on the antidiabetic activities of Cordyceps militaris extract in diet-streptozotocin-induced diabetic Sprague-Dawley rats. Biomed Res Int (2014) 0.90
Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus. Diabetes Metab Syndr Obes (2014) 0.86
Protein-tyrosine phosphatases are involved in interferon resistance associated with insulin resistance in HepG2 cells and obese mice. J Biol Chem (2012) 0.84
Metformin and the promise of geroprotection. Indian J Endocrinol Metab (2012) 0.82
Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells. Oncotarget (2015) 0.78
Metformin upregulates E-cadherin and inhibits B16F10 cell motility, invasion and migration. Oncol Lett (2015) 0.76
Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation. Mol Cancer Ther (2016) 0.76
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med (2002) 101.79
10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med (2008) 35.49
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet (1998) 34.34
Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest (2001) 23.21
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2008) 21.05
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet (2009) 15.00
Metformin and reduced risk of cancer in diabetic patients. BMJ (2005) 13.04
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol (2009) 10.18
Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care (2006) 7.99
Metformin. N Engl J Med (1996) 7.66
TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab (2009) 6.91
Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res (2009) 6.74
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med (1995) 6.51
New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care (2009) 6.17
The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med (2005) 5.76
Metformin: an update. Ann Intern Med (2002) 5.62
Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest (2010) 5.39
Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care (2005) 5.10
Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes (2005) 4.81
Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology (2009) 4.72
UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia (1991) 4.50
Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. J Clin Endocrinol Metab (2008) 4.29
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med (1995) 4.29
Metformin prevents tobacco carcinogen--induced lung tumorigenesis. Cancer Prev Res (Phila) (2010) 3.86
Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle (2009) 3.77
Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care (2010) 3.68
Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care (2003) 3.37
Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle (2009) 3.34
Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring) (2009) 3.15
Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. J Biol Chem (2004) 3.00
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev (2010) 2.91
Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care (2009) 2.90
Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res (2011) 2.53
Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control (2009) 2.49
Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes (2005) 2.46
Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice. Diabetologia (2010) 2.40
Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res (2009) 2.36
AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol (2010) 2.11
Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. Diabetes Care (2003) 2.02
Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocr Relat Cancer (2008) 1.96
Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med (2011) 1.93
The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle (2009) 1.89
Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila) (2010) 1.86
Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle (2010) 1.78
Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy. Gynecol Oncol (2009) 1.78
A case-control study of diabetes mellitus and cancer risk. Br J Cancer (1994) 1.76
Abnormal glucose tolerance and the risk of cancer death in the United States. Am J Epidemiol (2003) 1.75
Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr Relat Cancer (2010) 1.61
If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice. Aging (Albany NY) (2011) 1.61
Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program. Diabetes Care (2009) 1.48
Body size and shape changes and the risk of diabetes in the diabetes prevention program. Diabetes (2007) 1.45
Metformin therapy and clinical uses. Diab Vasc Dis Res (2008) 1.44
Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol (2011) 1.41
Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73. J Diabetes Complications (2006) 1.30
Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins. Gynecol Oncol (2011) 1.27
Factors associated with diabetes onset during metformin versus placebo therapy in the diabetes prevention program. Diabetes (2007) 1.25
Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51). Diabetologia (2001) 1.25
Metformin and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care (2010) 1.22
Long-term treatment with rosiglitazone and metformin reduces the extent of, but does not prevent, islet amyloid deposition in mice expressing the gene for human islet amyloid polypeptide. Diabetes (2005) 1.19
The global challenge of diabetes. Lancet (2008) 1.16
Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2. J Clin Endocrinol Metab (2003) 1.15
Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes. Diabetes Care (2006) 1.11
Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells. J Clin Endocrinol Metab (2010) 1.09
Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis. Diabetes Metab Rev (1995) 0.98
Effect of metformin on bile salt circulation and intestinal motility in type 2 diabetes mellitus. Diabet Med (1998) 0.95
Metformin suppresses hepatic gluconeogenesis and lowers fasting blood glucose levels through reactive nitrogen species in mice. Diabetologia (2010) 0.91
Differential effects of metformin on bile salt absorption from the jejunum and ileum. Diabetes Obes Metab (2003) 0.89
Metformin primarily decreases plasma glucose not by gluconeogenesis suppression but by activating glucose utilization in a non-obese type 2 diabetes Goto-Kakizaki rats. Eur J Pharmacol (2009) 0.84
The risk of endometrial cancer in diabetic and hypertensive patients: a nationwide record-linkage study in Finland. Ann Chir Gynaecol Suppl (1994) 0.80
Effects of metformin on bile salt transport by monolayers of human intestinal Caco-2 cells. Diabetes Obes Metab (2002) 0.77
The metabolically obese, normal-weight individual revisited. Diabetes (1998) 3.52
Branched-chain amino acid levels are associated with improvement in insulin resistance with weight loss. Diabetologia (2011) 1.93
Visceral adipose tissue: relationships between single slice areas at different locations and obesity-related health risks. Int J Obes (Lond) (2006) 1.42
Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes Obes Metab (2012) 1.34
Regulation of leptin production in humans. J Nutr (2000) 1.23
Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia (2013) 1.22
Truncal fat in relation to total body fat: influences of age, sex, ethnicity and fatness. Int J Obes (Lond) (2007) 1.14
C-terminal octapeptide of cholecystokinin decreases food intake in obese men. Physiol Behav (1982) 1.07
MRI-measured pelvic bone marrow adipose tissue is inversely related to DXA-measured bone mineral in younger and older adults. Eur J Clin Nutr (2012) 1.04
Sexual dimorphism in the energy content of weight change. Int J Obes Relat Metab Disord (2002) 0.97
Fat-free mass index: changes and race/ethnic differences in adulthood. Int J Obes (Lond) (2010) 0.96
Insulin, unlike food intake, does not suppress ghrelin in human subjects. J Clin Endocrinol Metab (2002) 0.95
Ethnic and sex differences in bone marrow adipose tissue and bone mineral density relationship. Osteoporos Int (2011) 0.92
Adiposopathy and bariatric surgery: is 'sick fat' a surgical disease? Int J Clin Pract (2009) 0.90
Gastric bypass surgery, but not caloric restriction, decreases dipeptidyl peptidase-4 activity in obese patients with type 2 diabetes. Diabetes Obes Metab (2011) 0.87
The relationship between serum levels of insulin and sex hormone-binding globulin in men: the effect of weight loss. J Clin Endocrinol Metab (1994) 0.86
Acarbose in the treatment of type I diabetes. Diabetes Care (1997) 0.85
[Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies]. Rev Med Suisse (2006) 0.84
[Somatocrinin induces growth hormone release in a case of growth hormone deficiency of hypothalamic origin in a child]. C R Seances Acad Sci III (1983) 0.83
Effects of acute experimental pancreatitis on insulin metabolism in the dog. Application of a new equilibrium infusion technic. Diabetes (1968) 0.82
Therapeutic controversy: Obesity--a modern-day epidemic. J Clin Endocrinol Metab (1999) 0.77
Obesity solutions: report of a meeting. Nutr Rev (1997) 0.77
Plasma leptin and acute serotoninergic stimulation of the corticotropic axis in women who are normal weight or obese. Obes Res (1997) 0.76
Physiologic effects of lowering caloric intake in nonhuman primates and nonobese humans. J Gerontol A Biol Sci Med Sci (2001) 0.76
Self-monitoring of blood glucose: tourniquet method. Diabetes Care (1988) 0.75
Measurement of percent body fat during weight loss in obese women. Comparison of four methods. Ann N Y Acad Sci (2000) 0.75
The NAASO position paper on approval and use of drugs to treat obesity. Obes Res (1995) 0.75
Temporal changes in bile acid levels and 12α-hydroxylation after Roux-en-Y gastric bypass surgery in type 2 diabetes. Int J Obes (Lond) (2016) 0.75
[Biological criteria of isolated Graves' ophthalmopathy]. Presse Med (1987) 0.75